Back Hepatitis C

Hepatitis C

AASLD 2016: 8-Week Triple Combo Cures Most Patients with Genotype 1-6 Hepatitis C

A 3-drug regimen of sofosbuvir, velpatasvir, and voxilaprevir taken for 8 weeks demonstrated an overall sustained virological response rate of 95% for previously untreated patients with all hepatitis C virus (HCV) genotypes, while a 12-week regimen cured 96%-97% of people who experienced prior treatment failure on direct-acting antivirals (DAAs), according to a set of Phase 3 studies presented last week at the AASLD Liver Meeting in Boston.

alt

AASLD 2016: AbbVie Pangenotypic Combination Cures 98% or More Across HCV Genotypes

AbbVie’s combination of glecaprevir and pibrentasvir cured at least 98% of people with hepatitis C in 3 large clinical trials covering 5 out of 6 genotypes of the virus, and it is likely to receive marketing approval in the United States and European Union as the first ribavirin-free pangenotypic direct-acting antiviral combination next year, according to a report at the AASLD Liver Meeting last week in Boston.

alt

AASLD 2016: Liver Cancer Risk Reduced After Hepatitis C Treatment, But Vigilance Needed

People who are cured of hepatitis C after a course of direct-acting antiviral treatment do not have a higher risk of developing hepatocellular carcinoma (HCC) -- and probably have a reduced risk -- according to studies from Italy and Canada presented at American Association for the Study of Liver Diseases (AASLD) Liver Meeting this week in Boston.

alt

AASLD 2016: AbbVie Pangenotypic Combination Cures Hard-to-Treat People with HCV Genotype 3

AbbVie’s pangenotypic combination of glecaprevir and pibrentasvir cured almost all of the hardest-to-treat genotype 3 hepatitis C patients -- those with cirrhosis or previous treatment experience -- in a Phase 2 trial, and looks suitable for use as an 8-week regimen for HCV genotypes 2, 4,5 and 6, according to results of studies presented at the AASLD Liver Meeting last week in Boston.

alt

IDWeek 2016: New Triple DAA Combo Cures 96%-99% of People with Genotype 1-6 Hepatitis C

A new 3-drug regimen of sofosbuvir, velpatasvir, and voxilaprevir, taken without ribavirin for 8 weeks, produced sustained virological response in 96% of previously untreated patients with all hepatitis C virus (HCV) genotypes, while a 12-week course cured 99% of treatment-experienced patients, researchers reported at the recent IDWeek meeting in New Orleans. Response rates dropped off, however, when treatment was shortened to 6 weeks.

alt

AASLD 2016: Grazoprevir/ Elbasvir + Sofosbuvir Highly Effective for Hard-to-Treat Genotype 3 HCV Patients

A triple regimen of grazoprevir/elbasvir (Zepatier) plus sofosbuvir (Sovaldi) without ribavirin cured 96% of previously untreated and 97% of treatment-experienced people with hepatitis C virus (HCV) genotype 3 and liver cirrhosis, matching rates seen in easier-to-treat patient groups, according to results from the C-ISLE study presented this week at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting in Boston.

alt

HIV Glasgow: Generic Hepatitis C Drugs Purchased Online Produce High Cure Rates

Use of generic versions of direct-acting antivirals for hepatitis C resulted in very high cure rates for people who obtained the products through 3 buyers’ clubs, indicating that the generic products are effective, according to a set of poster presentations at the International Congress on Drug Therapy in HIV Infection (HIV Glasgow) last week. People who purchased generic drugs were cured at a cost of around US$700-$900 in Southeast Asia and Eastern Europe, Andrew Hill of St. Stephen’s AIDS Trust reported.

alt

AASLD 2016: Real-World Responses to HCV Treatment Among U.S. Veterans Match Best Clinical Trial Results

Direct-acting antiviral treatment is curing people of hepatitis C in real-world clinical practice at similar rates to those seen in clinical trials, and there do not seem to be major differences between drug regimens, according to results of a large population study presented this weekend at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting in Boston.

alt

Over 1 Million People Have Been Treated with New Hepatitis Drugs, But Cost Remains a Barrier

More than 1 million people have now received hepatitis C treatment using the new highly effective and well-tolerated direct-acting antiviral agents despite their high cost, according to a report released this week by the World Health Organization. The Global Report on Access to Hepatitis C Treatment: Focus on Overcoming Barriers is available online.

alt